- Home
- CSTL vs ADTN Comparison
CSTL vs ADTN Comparison
Compare CSTL & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- ADTN
- Stock Information
- Founded
- CSTL 2007
- ADTN 1985
- Country
- CSTL United States
- ADTN United States
- Employees
- CSTL 784
- ADTN N/A
- Industry
- CSTL Medical Specialities
- ADTN Telecommunications Equipment
- Sector
- CSTL Health Care
- ADTN Telecommunications
- Exchange
- CSTL Nasdaq
- ADTN Nasdaq
- Market Cap
- CSTL 456.2M
- ADTN 616.5M
- IPO Year
- CSTL 2019
- ADTN 1994
- Fundamental
- Price
- CSTL $15.95
- ADTN $8.03
- Analyst Decision
- CSTL Strong Buy
- ADTN Strong Buy
- Analyst Count
- CSTL 6
- ADTN 4
- Target Price
- CSTL $37.67
- ADTN $12.00
- AVG Volume (30 Days)
- CSTL 527.3K
- ADTN 888.9K
- Earning Date
- CSTL 05-05-2025
- ADTN 05-07-2025
- Dividend Yield
- CSTL N/A
- ADTN N/A
- EPS Growth
- CSTL N/A
- ADTN N/A
- EPS
- CSTL N/A
- ADTN N/A
- Revenue
- CSTL $347,083,000.00
- ADTN $944,291,000.00
- Revenue This Year
- CSTL N/A
- ADTN $13.90
- Revenue Next Year
- CSTL $1.80
- ADTN $9.13
- P/E Ratio
- CSTL N/A
- ADTN N/A
- Revenue Growth
- CSTL 38.43
- ADTN N/A
- 52 Week Low
- CSTL $15.45
- ADTN $4.62
- 52 Week High
- CSTL $35.84
- ADTN $12.44
- Technical
- Relative Strength Index (RSI)
- CSTL 33.63
- ADTN 49.80
- Support Level
- CSTL $15.45
- ADTN $7.65
- Resistance Level
- CSTL $16.43
- ADTN $8.24
- Average True Range (ATR)
- CSTL 0.59
- ADTN 0.27
- MACD
- CSTL 0.04
- ADTN 0.02
- Stochastic Oscillator
- CSTL 15.93
- ADTN 37.62
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.